Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis

Blood

Volumn 126, Issue 19, 2015, Pages 2186-2192

  Wang, Yini ^a   Huang, Wenqiu ^a   Hu, Liangding ^b   Cen, Xinan ^c   Li, Lihong ^d   Wang, Jijun ^e   Shen, Jianliang ^f   Wei, Na ^a   Wang, Zhao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e PEKING UNIVERSITY THIRD HOSPITAL   (China)

^f NAVY GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; RITUXIMAB; CISPLATIN; PREDNISONE;

ACINETOBACTER INFECTION; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOPENIA; DRUG EFFICACY; DRUG RESPONSE; ENTEROBACTERIACEAE INFECTION; EPSTEIN BARR VIRUS; FOLLOW UP; HAND FOOT SYNDROME; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; SALVAGE THERAPY; SPLENECTOMY; STAPHYLOCOCCUS INFECTION; ADOLESCENT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; PREDNISONE; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84948947480     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-644914     Document Type: Article

References (26)

1. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3): 221-230.
2. Henter JI, Samuelsson-Horne A, Aricò M, et al; Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367-2373.
3. Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175-180.
4. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014; 383(9927):1503-1516.
5. Huang W, Wang Y, Wang J, et al. [Clinical characteristics of 192 adult hemophagocytic lymphohistiocytosis]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(9):796-801.
6. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
7. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15): 4041-4052.
8. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101-109.
9. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritisassociated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23-27.
10. Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(1):59-61.
11. Imashuku S, Hibi S, Ohara T, et al; Histiocyte Society. Effective control of Epstein-Barr virusrelated hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93(6):1869-1874.
12. Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747-749.
13. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154-5157.
14. Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622-e628.
15. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol. 2002;44(3):259-272.
16. Shin HJ, Chung JS, Lee JJ, et al. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008; 23(3):439-444.
17. Chellapandian D, Das R, Zelley K, et al; EBV-HLH Rituximab Study Group. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376-382.
18. Huwyler J, Drewe J, Krähenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine. 2008;3(1):21-29.
19. Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharm Res. 2001;18(6): 780-787.
20. Lin TF, Ferlic-Stark LL, Allen CE, Kozinetz CA, McClain KL. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011;56(1):154-155.
21. Wang Y, Wang Z, Wu L, et al. [A multicenter retrospective analysis of diagnosis and treatment on 72 hemophagocytic syndrome cases.] Zhonghua Xue Ye Xue Za Zhi. 2009;30(12): 793-798.
22. Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology (Am Soc Hematol Educ Program). 2013;2013:605-611.
23. Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139(6): 713-727.
24. Ahn JS, Rew SY, Shin MG, et al. Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2010;85(9): 719-722.
25. Tateishi Y, Oda S, Sadahiro T, et al. Continuous hemodiafiltration in the treatment of reactive hemophagocytic syndrome refractory to medical therapy. Transfus Apheresis Sci. 2009;40(1): 33-40.
26. Imashuku S, Kuriyama K, Sakai R, et al. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBVHLH) in young adults: a report from the HLH study center. Med Pediatr Oncol. 2003;41(2): 103-109.